Drugs / Mo-Rez
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06796907 | Mar 2025 → Jun 2027 expected | female reproductive system neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mo-Rez | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06796907 ↗ |
| Known as | Mocertatug Rezetecan | “This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines.” NCT06796907 ↗ |
| Route | Intravenous | “Mo-Rez will be administered intravenously (IV).” NCT06796907 ↗ |